Healthy Subjects
Conditions
Keywords
[14C] SY-5007, Mass Balance
Brief summary
This is a single-center, open-label, non-randomized, single dose study in healthy male subjects designed to assess mass balance recovery, metabolite profile and metabolite identification of radio-labeled SY-5007 administered orally.
Detailed description
The trial will consist of two parts: Pilot Study: Two eligible adult male subjects will be enrolled and admitted to the clinical trial center after passing the inclusion criteria review. They will undergo training on medication administration, urine and feces collection, etc., to ensure compliance with the protocol and standard operating procedures (SOP). Subjects will fast before medication administration and provide urine and feces samples at specified intervals after dosing. Blood samples will also be collected at specified time points. Formal Study: Four to six male subjects will be enrolled, receiving a single dose of SY-5007 160 mg orally containinig roughly 120 µCi \[14C\] SY-5007. Blood, urine and feces samples will be collected at specified time points. Safety monitoring (12-lead ECG, vital signs, blood chemistry and haematology) and adverse events will be monitored throughout the study.
Interventions
DRUG[14C] SY-5007
Carbon-14 labeled SY-5007
Sponsors
Shouyao Holdings (Beijing) Co. LTD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
Subjects must meet all of the following criteria to be enrolled in this study: 1. Fully informed, able to communicate effectively with researchers, agree to abide by the protocol and trial management regulations, and voluntarily sign the written Informed Consent Form (ICF); 2. Healthy adult males aged 18 to 50 years at the time of signing the ICF, with no plans for reproduction or sperm donation within the past 2 years; 3. Weight ≥ 50 kg and body mass index (BMI) between 18 and 26 kg/m2; 4. Subjects of reproductive capability agree to employ effective contraceptive measures with their sexual partners during the study period and for 2 years following the end of the study.
Exclusion criteria
Subjects meeting any of the following criteria are ineligible for participation in this study: 1. History of allergies (such as allergies to two or more drugs, foods, or pollen, or individuals prone to skin hives or allergic reactions). 2. Positive for hepatitis B surface antigen, hepatitis C virus antibodies, human immunodeficiency virus antibodies, or positive for syphilis treponemal and non-treponemal antibodies during screening. 3. Abnormal clinically significant vital signs, physical examinations, laboratory tests, or electrocardiograms at screening. 4. Gastrointestinal, hepatic, or renal diseases that may affect drug pharmacokinetics as assessed by the investigator at screening. 5. History of drug abuse or illicit drug use within 12 months prior to the first dose administration, or positive urine drug screening test during screening. 6. Underwent major surgery within 6 months prior to the first dose administration, or planned to undergo surgery during the trial period. 7. History of any clinically significant illness within 3 months prior to the first dose administration or conditions deemed by the investigator to potentially affect trial outcomes, including but not limited to cardiovascular, endocrine, nervous, respiratory, digestive, urinary, hematologic, immune, or psychiatric disorders. 8. Average daily smoking of more than 5 cigarettes within 3 months prior to the first dose administration, or unwillingness to discontinue use of any tobacco products during the trial. 9. Regular alcohol consumption within 3 months prior to the first dose administration \[defined as consuming more than 14 units of alcohol per week (1 unit = 360mL of 5% alcohol beer or 45mL of 40% alcohol liquor or 150mL of 12% alcohol wine)\], or inability to abstain from alcohol during the trial, or positive alcohol breath test during screening. 10. History of blood donation or significant blood loss (≥ 300mL) within 3 months prior to the first dose administration, or use of blood products or blood transfusion within 1 month prior to the first dose administration. 11. Participation in other drug or medical device clinical trials within 3 months prior to the first dose administration (excluding screen failures), or prior use of the investigational drug. 12. Vaccination within 1 month prior to the first dose administration. 13. Use of any prescription drugs, over-the-counter drugs, supplements, or herbal remedies within 2 weeks prior to the first dose administration (if the half-life \[t1/2\] of the drug can be confirmed, a washout period of 5 times of t1/2 is required). 14. Habitual consumption of more than 8 cups (1 cup = 250mL) of tea, coffee, or caffeinated beverages and unable to abstain from consumption within 48 hours prior to the first dose administration and during the trial. 15. Special dietary requirements or difficulty swallowing. 16. Habitual constipation or previous difficulty with bowel movements. 17. Difficulty with blood collection, history of fainting with needles, or intolerance to venipuncture. 18. Engagement in occupations requiring prolonged exposure to radioactive conditions; or significant exposure to radiation within 1 year prior to the trial (e.g., 2 chest/abdominal CT scans, or 3 other types of X-ray examinations). 19. History of definite neurological or psychiatric disorders, including dementia or seizures diagnosed for any reason. 20. Other conditions deemed unsuitable for participation in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Metabolic profiling in plasma, urinary and fecal excretion | At pre-dose and up to 2 weeks post-dose | To characterize the metabolic profile and identify circulating and excreted metabolites of SY-5007 using liquid chromatography with mass spectral detection. |
| Total radioactivity in plasma PK: Tmax | At pre-dose and up to 2 weeks post-dose | Time to reach the Cmax |
| Total radioactivity in plasma PK: AUC0-t | At pre-dose and up to 2 weeks post-dose | Defined as area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration |
| Total radioactivity in plasma PK: t½ | At pre-dose and up to 2 weeks post-dose | Defined as apparent plasma terminal phase disposition half-life |
| Total radioactivity in plasma PK: CL/F | At pre-dose and up to 2 weeks post-dose | Defined as apparent total body clearance |
| Whole blood to plasma total radioactivity ratio | At pre-dose and up to 2 weeks post-dose | To evaluate the extent of distribution of total radioactivity into blood cells |
| Cumulative total radioactivity in urine and faeces | At pre-dose and up to 2 weeks post-dose | Mass balance recovery of total radioactivity in all (urine, faeces) amount excreted (Ae) expressed as a percentage of the administered dose (%Ae) |
| Total radioactivity in plasma PK: Cmax | At pre-dose and up to 2 weeks post-dose | Highest radioactivity observed plasma concentration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tmax of SY-5007 and its metabolites | At pre-dose and up to 2 weeks post-dose | Defined as time to maximum plasma concentration |
| AUC0-t of SY-5007 and its metabolites | At pre-dose and up to 2 weeks post-dose | Defined as area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration |
| t½ of SY-5007 and its metabolites | At pre-dose and up to 2 weeks post-dose | Defined as apparent plasma terminal phase disposition half-life |
| CL/F of SY-5007 and its metabolites | At pre-dose and up to 2 weeks post-dose | Defined as apparent total body clearance |
| Incidence of adverse events | At pre-dose and up to 2 weeks post-dose | To evaluate the safety of a single oral dose of 160 mg of SY-5007 |
| Cmax of SY-5007 and its metabolites | At pre-dose and up to 2 weeks post-dose | Defined as maximum observed plasma concentration |
Countries
China
Contacts
Primary ContactYinghui Sun, PhD
Outcome results
None listed